Company: ARTL
Filing Date: 2025-07-18
Form Type: 424B5
Source: 0001640334-25-001239
Chunk: 27

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-07-18
Form: 424B5
Chunk 27
---
 below which sales may not be made. Once we have so instructed Lafferty, unless Lafferty declines to accept the terms of such notice in accordance with the Sales Agreement, Lafferty has agreed to use its reasonable best efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Lafferty under the Lafferty Agreement to sell our shares of common stock are subject to a number of conditions that we must meet. We or Lafferty may suspend the offering of shares of common stock being made through Lafferty under the Sales Agreement upon proper notice to the other party.

The settlement of sales of shares between us and Lafferty is generally anticipated to occur on the first trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Lafferty may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

We will pay Lafferty a commission equal to 2.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock by Lafferty. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse Lafferty for the fees and disbursements of its counsel, payable upon execution of the Sales Agreement, in an amount not to exceed $50,000, in addition to up to $5,000 per “Representation Date” in connection with ongoing diligence arising from the transactions contemplated by the Sales Agreement. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares. We will report at least quarterly the number of shares of common stock sold through Lafferty under the Sales Agreement, the net proceeds to us and the compensation paid by us to Lafferty in connection with the sales of our common stock.

Lafferty is not required to sell any certain number of shares or dollar amount of our common stock, but will use its reasonable best efforts consistent with its normal trading and sales practices to sell on our behalf all of the shares of common stock requested to be sold by us, subject to the conditions set forth in the Sales Agreement. In connection with the